EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte Studie

Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)

Tislelizumab kombiniert mit Induktionschemotherapie und gleichzeitiger Chemoradiotherapie bei lokal fortgeschrittenem Ösophagus-Plattenepithelkarzinom: multizentrische randomisierte Phase-II-Studie (EC-CRT-002)

Baoqing Chen iD, Shiliang Liu iD, Yujia Zhu, Jingjing Zhang, Yong Bao iD, Fanjun Meng, Li Zhang, Xingyuan Cheng, Wendi Xuzhang, Biqi Chen, Ruixi Wang, Zimeng Li und 9 weitere

Journal of Clinical Oncology · 01.06.2026 · 44 (16) · 1508-1519

DOI: 10.1200/jco-25-03044 ↗

Auf einen Blick

Bei lokal fortgeschrittenem, nicht resektablem ESCC war Tislelizumab ohne Erhaltungstherapie mit besserem progressionsfreiem und Gesamtüberleben verbunden. Mit Erhaltungstherapie zeigte sich kein PFS-Vorteil.

Fragestellung

Verbessert Tislelizumab zusätzlich zu Induktionschemotherapie und gleichzeitiger CRT bei nicht resektablem, lokal fortgeschrittenem ESCC Wirksamkeit und Sicherheit?

Methode

Multizentrische, randomisierte, offene Phase-II-Studie in 4 akademischen Krankenhäusern in China; 1:1-Randomisierung; Vergleich mit historischem Kontrollkollektiv.

Ergebnisse

114 Patient:innen; Gruppe A n = 57, Gruppe B n = 57. 1-Jahres-PFS: 71,9 % vs. 56,4 %; HR 0,54 (95 %-KI 0,32–0,94) in Gruppe B, Gruppe A 52,6 %; HR 1,06 (95 %-KI 0,67–1,68). Gesamtüberleben in Gruppe B besser: HR 0,42 (95 %-KI 0,22–0,82).

Schlussfolgerung der Autor:innen

Die Zugabe von Tislelizumab zu Induktionschemotherapie und gleichzeitiger CRT ohne Erhaltungstherapie zeigte bei lokal fortgeschrittenem ESCC eine bessere Wirksamkeit bei beherrschbarer Toxizität.

Kernaussagen

  • 1-Jahres-PFS in Gruppe B besser als historische Kontrolle: 71,9 % vs. 56,4 %
  • Gesamtüberleben in Gruppe B verbessert: HR 0,42 (95 %-KI 0,22–0,82)
  • Schwere AEs traten bei 86,0 % und 80,7 % auf

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2026. Verfasst von Baoqing Chen und 20 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzho…. Hauptthemen laut MEDLINE: Induction Chemotherapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Chemoradiotherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 28 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate the efficacy and safety of adding tislelizumab to induction chemotherapy and concurrent chemoradiotherapy (CRT), with or without maintenance immunotherapy, in patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). METHODS This multicenter, randomized, open-label, phase II trial was conducted across four academic hospitals in China (ClinicalTrials.gov identifier: NCT05520619 ). Participants were adults age 18-70 years with newly diagnosed, unresectable, stage II to IVB ESCC. Patients were randomly assigned (1:1) to receive two cycles of paclitaxel/cisplatin induction chemotherapy followed by concurrent CRT in combination with tislelizumab for 16 cycles in group A (two induction, two concurrent, and 12 maintenance) or four cycles in group B (two induction and two concurrent). The primary end point was progression-free survival (PFS) in the intention-to-treat population, compared with historical control. RESULTS Between October 2022 and October 2024, 114 patients were randomly assigned to group A (n = 57) or group B (n = 57). After a median follow-up of 22.7 months (IQR, 16.2-28.2), group B demonstrated significantly better PFS versus controls (1-year: 71.9% [95% CI, 61.1 to 84.6] v 56.4% [95% CI, 44.7 to 71.1]; hazard ratio [HR], 0.54 [95% CI, 0.32 to 0.94]), while group A showed no PFS benefit (1-year: 52.6% [95% CI, 41.4 to 67.3]; HR, 1.06 [95% CI, 0.67 to 1.68]). Overall survival was also significantly better in group B (HR, 0.42 [95% CI, 0.22 to 0.82]). Grade ≥3 adverse events occurred in 86.0% of group A and 80.7% of group B, with the most common being lymphopenia (77.2% and 73.7%, respectively). Comprehensive biomarker analyses revealed that PD-L1 expression, CD8 + T-cell density, NRF2 pathway mutations, and dynamic changes in circulating tumor DNA were associated with treatment efficacy. CONCLUSION The addition of tislelizumab to induction chemotherapy and concurrent CRT without maintenance immunotherapy demonstrated superior efficacy and manageable toxicity in locally advanced ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Induction ChemotherapyEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsChemoradiotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMiddle AgedFemaleMaleAgedAdultCisplatinPaclitaxelYoung AdultProgression-Free SurvivalChina

Substanzen

CisplatinPaclitaxel

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.
  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co, Ltd, Guangzhou, China.
  • Department of Radiation Oncology, Zhongshan City People's Hospital, Zhongshan, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Radiation Oncology, Jieyang People's Hospital, Jieyang Affiliated Hospital, Sun Yat-sen University, Jieyang, China.

ORCID-Profile: Baoqing Chen, Shiliang Liu, Yong Bao, Jibin Li, Qiaoqiao Li, Hong Yang, Mian Xi

Zitieren

APA

Chen, B., Liu, S., Zhu, Y., Zhang, J., Bao, Y., Meng, F., Zhang, L., Cheng, X., Xuzhang, W., Chen, B., Wang, R., Li, Z., Hu, Y., Liu, M., Lv, Y., Li, J., Dragomir, M. P., Chen, M., Li, Q., …, & Xi, M. (2026). Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002). Journal of Clinical Oncology, 44(16), 1508-1519. https://doi.org/10.1200/jco-25-03044

Vancouver

Chen B, Liu S, Zhu Y, Zhang J, Bao Y, Meng F, et al. Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002). Journal of Clinical Oncology. 2026;44(16):1508-1519. doi:10.1200/jco-25-03044

BibTeX
@article{Chen2026,
  author = {Chen, Baoqing and Liu, Shiliang and Zhu, Yujia and Zhang, Jingjing and Bao, Yong and Meng, Fanjun and Zhang, Li and Cheng, Xingyuan and Xuzhang, Wendi and Chen, Biqi and Wang, Ruixi and Li, Zimeng and Hu, Yonghong and Liu, Mengzhong and Lv, Yingxin and Li, Jibin and Dragomir, Mihnea P and Chen, Ming and Li, Qiaoqiao and Yang, Hong and Xi, Mian},
  title = {Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002)},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {16},
  pages = {1508--1519},
  doi = {10.1200/jco-25-03044}
}
Kostenlos starten →